Search clinical trials for: Imatinib Mesylate

Total 2418 results

National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Gastrointestinal Stromal Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Prostate Cancer | Metastatic Cancer

United States
Peking University

Completed

Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

China
Technical University of Munich

Completed

Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer

Gastric Cancer

Germany
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Recurrent Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Adult Fibrosarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Philadelphia Positive Chronic Myeloid Leukemia

United States, Germany, United Kingdom, France, Italy
Memorial Sloan Kettering Cancer Center

Active, not recruiting

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor (GIST)

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Prostate Cancer

United States
Amneal Pharmaceuticals, LLC
Accutest Research Laboratories (I) Pvt. Ltd.

Completed

Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

India
University of Southern California
Novartis

Completed

Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

Colorectal Cancer | Colon Cancer

United States
Samsung Medical Center

Active, not recruiting

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Advanced, Refractory Cancer

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Novartis Pharmaceuticals

Completed

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors

Italy
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Carcinoma, Adenoid Cystic | Cancer of the Head and Neck

France
Hospices Civils de Lyon

Unknown

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Acute Lymphocytic Leukemia

France
Oslo University Hospital
University Hospital of North Norway; Helse Stavanger HF; Haukeland University... and other collaborators

Not yet recruiting

Precision Cancer Therapy in Rare Cancers (MATRIX-Rare)

Rare Malignant Neoplasm
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
Yonsei University

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Fibromatosis

Korea, Republic of
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Cttq
Ruijin Hospital

Unknown

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Completed

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States
Abramson Cancer Center at Penn Medicine
Novartis Pharmaceuticals

Terminated

Study of Temzolomide and Gleevec in Advanced Melanoma

Melanoma | Advanced Melanoma

United States
Medical University of South Carolina
Columbia University

Completed

LAM Pilot Study With Imatinib Mesylate (LAMP-1)

Lymphangioleiomyomatosis

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

Solid Tumor | Thyroid Cancer

United States
HK inno.N Corporation

Completed

to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers

Healthy

Korea, Republic of
Istituto Scientifico H. San Raffaele

Unknown

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

Brain and Central Nervous System Tumors

Italy
Duke University
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Brain and Central Nervous System Tumors

United States
SCRI Development Innovations, LLC
Novartis; Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
University Hospital, Bordeaux

Completed

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)

Chronic Myeloid Leukaemia

France
Kerman University of Medical Sciences

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Chronic Myelogenous Leukemia

Iran, Islamic Republic of
Novartis

Completed

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Healthy
Assistance Publique Hopitaux De Marseille

Unknown

Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (GIGIST)

Gastrointestinal Stromal Tumor
Novartis Pharmaceuticals

Terminated

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (IMPRES Extn)

Pulmonary Arterial Hypertension

Spain, Germany, Belgium, Switzerland, United States, Netherlands, Austria, Canada, Korea, Republic of, Italy, Japan, United Kingdom, France
Novartis Pharmaceuticals

Terminated

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Germany, Belgium, United Kingdom, United States, Lithuania, Italy, Australia

Search clinical trials for: Imatinib Mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations